German pharma giant Bayer is uniting with researchers at Johns Hopkins University to ferret out new treatments for retinal diseases, signing a 5-year deal targeting early-stage R&D.
Respiratory biotech Pulmatrix has completed its nontraditional path to the public markets, closing a merger with upstart Ruthigen to inherit a Nasdaq listing, at the same time banking $10 million and partnering up with generics giant Mylan.
A mystery Chinese investor ventured $30 million on San Diego-based BioAtla, which is developing early stage biologics activated in selective microenvironments. In a release, BioAtla noted potential applications in monoclonal antibodies, bispecific antibodies, antibody drug conjugates, immune checkpoint inhibitors and CAR-T cells.
Illumina and Chinese genomics company Annoroad are joining forces to develop noninvasive prenatal screening tools based on next-generation sequencing technology, a potentially fruitful collaboration as Illumina looks to gain ground in emerging markets and strengthen its foothold in a saturated prenatal testing field.
Antiviral drug developer ContraVir Pharmaceuticals is working with ImageIQ on its Phase III program for a new shingles treatment, tapping the company for its imaging expertise.
Johnson & Johnson has hit a milestone--with more than 200 collaborations formed through its Johnson & Johnson Innovation that was launched in 2013. The latest crop of 17 new collaborations with research institutions and healthcare companies brings with it at least 5 that clearly could help advance the state of med tech.
Swedish CRO TFS is working with local biotech LobSor Pharmaceuticals on a new treatment for Parkison's disease, agreeing to share the risks and potential rewards of the development process.
Chinese CRO WuXi PharmaTech is joining forces with the gene therapy experts at ReGenX Bio to hammer out a manufacturing process for the company's potential one-time treatments.
Under the "Make in India" initiative, India and the Netherlands signed a memorandum of understanding enabling Bharat Immunologicals and Biologicals, a public-sector biotech under India's department of biotechnology, to develop a measles and rubella vaccine with the assistance of the Netherlands' government-based Translational Vaccinology.
Johnson & Johnson today took the wraps off its latest collection of collaborations aimed at everything from setting up new "asset-centric" drug development operations with a partner in China to exploring ways to prevent Type 1 diabetes with investigators at Washington University. Its latest tally of 17 new deals and developments also includes a new Innovation hub in Sweden and brings its global total for its deal teams to more than 200 projects over two years running.